中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

替吉奥联合经肝动脉化疗栓塞治疗中晚期肝细胞癌的疗效观察

张呈 陈昌南 林云笑 苏铭俊 潘岐作 陈婵娟 容庭杰 谢峰

引用本文:
Citation:

替吉奥联合经肝动脉化疗栓塞治疗中晚期肝细胞癌的疗效观察

DOI: 10.3969/j.issn.1001-5256.2014.01.012
详细信息
  • 中图分类号: R735.7

Clinical effect of transcatheter arterial chemoembolization combined with tegafur, gimeracil, and oteracil potassium in treatment of advanced hepatocellular carcinoma

  • 摘要:

    目的对比观察经肝动脉栓塞化疗(TACE)单用或联合替吉奥治疗中晚期肝细胞癌(HCC)的疗效。方法将2009年8月-2010年10月本院收治的无法手术切除的中晚期HCC患者60例随机分为2组,每组30例。治疗组采用TACE联合替吉奥口服,对照组仅行TACE。观察2组的有效率、疾病控制率、生存率以及不良反应情况。计数资料采用χ2检验;生存分析运用Logrank检验。结果有效率:治疗组63.3%,对照组33.3%,差异有统计学意义(χ2=5.406,P=0.020);疾病控制率:治疗组86.7%,对照组43.3%,差异有统计学意义(χ2=12.308,P=0.000)。1年生存率:治疗组77.3%,对照组51.5%,差异有统计学意义(χ2=4.593,P=0.032);2年生存率:治疗组34.8%,对照组10.4%,差异有统计学意义(χ2=4.812,P=0.028)。治疗组、对照组不良反应轻微,主要是恶心呕吐、腹泻和骨髓抑制,为1、2级,对症治疗可缓解,两组比较差异无统计学意义(P>0.05)。结论替吉奥联合TACE术对中晚期HCC有一定的治疗价值,值得进一步探讨。

     

  • [1]KIM SJ, HAN SW, OH DY, et al.Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma[J].Anticancer Res, 2010, 30 (12) :5245-5250.
    [2]MORISE Z, SUGIOKA A, FUJITA J, et al.S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas[J].Hepatogastroenterology, 2007, 54 (80) :2315-2318.
    [3]NAKAMURA M, NAGANO H, MARUBASHI S, et al.S-1 treatment against advanced HCC[J].Gan To Kagaku Ryoho, 2006, 33 (Suppl 1) :230-235.
    [4]KATAMURA Y, AIKATA H, HASHIMOTO Y, et al.Pilot study of systemic combination therapy with S-1, an oral fluoropyrimidine, and cisplatin for hepatocellular carcinoma with extrahepatic metastases[J].Hepatogastroenterology, 2010, 57 (102-103) :1272-1278.
    [5]YAMADA D, WADA H, KOBAYASHI S, et al.A long-term survival case of hepatocellular carcinoma with bone metastasis and inferior vena cava tumor thrombus successfully treated with multidisciplinary therapy[J].Gan To Kagaku Ryoho, 2010, 37 (12) :2670-2267.
    [6]YANG BH, XIA JL.Clinical diagnosis and staging criteria for primary liver cancer[J].Chin J Hepatol, 2001, 9 (6) :324. (in Chinese) 杨秉辉, 夏景林.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 2001, 9 (6) :324.
    [7] MAO JW.Current situation and progress in minimally inva-sive therapy for primary liver cancer[J].Chin Modern Med, 2005, 3 (7) :29-31. (in Chinese) 毛金武.原发性肝癌微创治疗的现状及进展[J].中华当代医学, 2005, 3 (7) :29-31.
    [8]LYU HF, ZHANG YX, HAN LL, et al.Clinical observation of Oxaliplatin combined with Gimeracil or Capecitabine in the treatment of advanced gastric cancer in elderly patients[J].China Med Herald, 2012, 9 (23) :61-63. (in Chinese) 吕慧芳, 张延新, 韩黎丽, 等.奥沙利铂联合替吉奥或卡培他滨治疗老年晚期胃癌的临床观察[J].中国医药导报, 2012, 9 (23) :61-63.
    [9]BLUM M, SUZUKI A, AJANI JA.A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma[J].Future Oncol, 2011, 7 (6) :715-726.
    [10]SAIF MW, SYRIGOS KN, KATIRTZOGLOU NA.S-1:a promising new oral fluoropyrimidine derivative[J].Expert Opin Investig Drugs, 2009, 18 (3) :335-348.
    [11]LIU JH, QI SM, CHEN GJ, et al.Compourd tegafur capsules for clinical research progress[J].China Modern Doctor, 2008, 46 (30) :62-63.刘江华, 戚苏明, 陈国俊, 等.替吉奥胶囊临床研究进展[J].中国现代医生, 2008, 46 (30) :62-63.
    [12]VARGA M, VALSAMIS A, MATIA I, et al.Transarterial chemoembolization in hepatocellular carcinoma[J].Rozhl Chir, 2009, 88 (8) :434-438.
    [13]LAN CH, WANG CY.Progress of TACE for primary liver cancer[J].Current Physician, 2009, 3 (4) :500-502.兰春虎, 王常友.原发性肝癌TACE治疗进展[J].当代医学, 2009, 3 (4) :500-502.
    [14]CHEN CN, PAN QZ, HUANG HX, et al.Clinical effect of whole-body hyperthermia combined with transcatheter arterial chemoembolization in treatment of advanced liver cancer[J].J Clin Hepatol, 2006, 33 (3) :220. (in Chinese) 陈昌南, 潘岐作, 黄活勋, 等.体外热疗与TACE结合治疗中晚期肝癌的临床研究[J].临床肝胆病杂志, 2006, 33 (3) :220.
  • 加载中
计量
  • 文章访问数:  2835
  • HTML全文浏览量:  10
  • PDF下载量:  590
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-02-09
  • 出版日期:  2014-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回